Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: The Framingham heart study

JAMA

Volumn 288, Issue 10, 2002, Pages 1252-1259

  Vasan, Ramachandran S ^a,b   Benjamin, Emelia J ^a,b   Larson, Martin G ^a,b   Leip, Eric P ^a   Wang, Thomas J ^a,c   Wilson, Peter W F ^a,b   Levy, Daniel ^a,b,c,d  

^a FRAMINGHAM HEART STUDY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 0037063415     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.10.1252     Document Type: Article

References (43)

1. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
2. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial
3. Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure?
4. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study
5. Limited echocardiography for hypertensive left ventricular hypertrophy
6. Biochemical detection of left-ventricular systolic dysfunction
7. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care
8. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide
9. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy
10. Comparison of atrial natriuretic peptide B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction
11. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population
12. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction
13. Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: Observational study
14. Screening for cardiac dysfunction in asymptomatic patients by measuring B-type natriuretic peptide levels
15. An investigation of coronary heart disease in families: The Framingham Offspring Study
16. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements
17. Echocardiographic assessment of left ventricular hypertrophy
18. Simplified echocardiography in the diagnosis of heart failure
19. Percentage of shortening of the echocardiographic left ventricular dimension: Its use in determining ejection fraction and stroke volume
20. The meaning and use of the area under a receiver operating characteristic (ROC) curve
21. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors
22. A method of comparing the areas under receiver operating characteristic curves derived from the same cases
23. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
24. Some risk factors related to the annual incidence of cardiovascular disease and death in pooled repeated biennial measurements
25. Prevalence-value-accuracy plots: A new method for comparing diagnostic tests based on misclassification costs
26. When can a risk factor be used as a worthwhile screening test?
27. Index for rating diagnostic tests
28. Impact of age and sex on plasma natriuretic peptide levels in healthy adults
29. Users' guides to the medical literature, III: How to use an article about a diagnostic test, B: What are the results and will they help me in caring for my patients?
30. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction
31. Cohort study of plasma natriuretic peptides for identifying left ventricular systolic dysfunction in primary care
32. Clinical criteria and biochemical markers for the detection of systolic dysfunction
33. Meta-analysis of Pap test accuracy
34. Enhancing and evaluating diagnostic accuracy
35. Predictive properties of serum-prostate-specific antigen testing in a community-based setting
36. Circulating N-terminal proatrial natriuretic peptide is an independent predictor of left ventricular hypertrophy in the general population: The Tromso Study
37. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population
38. Gender-specific differences of cardiac remodeling in subjects with left ventricular dysfunction: A population-based study
39. Ruling out or ruling in disease with the most sensitive or specific diagnostic test: Short cut or wrong turn?
40. Cohort study of plasma natriuretic peptides for identifying left ventricular systolic dysfunction in primary care
41. Left ventricular diastolic function in hypertension: Relation to left ventricular mass and systolic function
42. Heart rate recovery immediately after treadmill exercise and left ventricular systolic dysfunction as predictors of mortality